🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

THE CONQUER STUDY We, the ASCO IDEA Awardees 2024 are conducting a worldwide survey on the use of oncology guidelines. Please help us fill our survey for us to share the results in #ASCO2025 forms.office.com/r/36zG6HfgYY Julie Gralow G Curigliano MD PhD Sara Tolaney OncoAlert Stephanie Graff, MD, FACP, FASCO Tatiana Prowell, MD

Radiotherapy and Nuclear Medicine Equipment Shortages in Vietnam: A Critical Gap in Cancer Care. Learn more: brnw.ch/21wR7y3 #RadOnc

I'm excited to share our recently published article on the treatment of breast cancer with brain metastases in Vietnam, where access to newer systemic therapies with intracranial activity remains very limited. Technology in Cancer Research & Treatment journal journals.sagepub.com/doi/10.1177/15…

I had an amazing experience at The Royal Marsden NHS Foundation Trust during the 2-month ESMO Clinical Unit Visit. I gained valuable insights not only into breast cancer but also care delivery, quality improvement, and research. A huge thank to ESMO - Eur. Oncology , #ICF and my great mentor Nicolò Battisti, MD 😊

It’s been my pleasure to work with Long Nguyen who has joined the The Royal Marsden NHS Foundation Trust Breast Unit for two months from beautiful Vietnam 🇻🇳 Long is a brilliant oncologist and I thoroughly enjoyed our discussions in the clinic about patient management and the complexities of

Happy to share that two Common Sense Oncology projects have been accepted for poster presentation at #ASCO25 Looking forward to discussing our findings 😊

Excited to share our work from the #BRCABCYcollaboration presented at #SABCS24 now out in The Lancet Oncology: risk-reducing surgeries are associated with major survival improvement in young #BRCA carriers with #BreastCancer OncoAlert Eva Blondeaux Free link: urlsand.esvalabs.com/?u=https%3A%2F…

Huge news. New version of ESMO-MCBS is out! Introducing ESMO-MCBS v 2.0 with 13 new updates! Check it out today. Congratulations to the ESMO - Eur. Oncology -MCBS working group for the continued efforts to improve the tool and make it relevant and more valid. annalsofoncology.org/article/S0923-…

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25

Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:

Most awaited data for #ASCO25 DESTINY-Breast09 1L T-DXd + P 💥 vs THP in HER2+ mBC 🧪 PFS (INV): 40.7 mo vs 20.7 mo HR 0.49 (0.39–0.61) 🎯 PFS (BICR): 40.7 vs 26.9 mo HR 0.56 (0.44–0.71), p<0.00001 📈 24-mo PFS: 70.1% vs 52.1% ✅ CR rate: 15.1% vs 8.5% 🕒 DoR >3 yrs ⚠️ No new

Would it be SOC in 1st line to give T-Dxd+ P throughout the median duration of 40 months or ~6 cycles then maintenance as in CLEOPATRA? Upfront T-Dxd in 1st line better than giving it in 2nd line in terms of OS? Any biomarkers other than Her2?

🔥NSABP- B51 is out! Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer 👉longer follow up desired 👉applicability across subtypes? 👉Impact of more modern systemic therapies ? NRG Oncology ASTRO #BreastCancer nejm.org/doi/full/10.10…

Join us for a special CSO webinar on June 19 where we discuss some important takeaways from #ASCO25, CSO style. Registration link: queensu.zoom.us/meeting/regist…

International Clinical Research Scholars Program – Asia Pacific is now accepting applications Please find a link to the application here: asco.smapply.org/prog/ICRS_Asia… ASCO #ASCOAsiaPacificRegionalCouncil

📢 The ASCO #International #ClinicalResearch Scholars Program 🧑‍🎓👩‍🎓🥼🏥 for #AsiaPacific is now open for application! ✍️ We are seeking #enthusiastic colleagues for this #inaugural cohort who are keen to learn from experts on research #methodologies, #leadership & #grantwriting